Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo
FEV1 % predicted: relative change from baseline · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 76 participantsLow